Moderna Scales Up Manufacturing with Two New Production Agreements

Moderna has struck a fill-and-finish deal with Thermo Fisher Scientific to produce hundreds of millions of doses of Moderna’s messenger RNA-based COVID-19 vaccine at its Greenville, N.C., plant.

Moderna has also expanded an existing agreement with Lonza to manufacture drug substances for its booster vaccine candidate aimed at variant SARS-CoV-2 strains. Under the deal, Lonza will establish a new production facility in the Netherlands and help manufacture up to 300 million additional doses of the booster vaccine annually.

Through the new Lonza deal and a previously announced agreement with Rovi for drug substance manufacturing in Granada, Spain, Moderna now expects to supply 600 million booster variant vaccine doses to the EU per year.